D07001 GemOral

D07001 GemOral
Product Description

GemOral, or oral gemcitabine, was developed by INNOPHARMAX with proprietary OralPAS® system.

  • GemOral is the best-in-class, low dose oral metronomic chemotherapy product for cancer patients
  • GemOral is Low dose, low toxicity, shows no sign of myelosuppression, and no side effect of hematological issues commonly seen in conventional injection treatment
  • New treatment mechanism: low dose metronomic treatment promotes innate immunity and enhances anti-tumor effect, allowing the frail body to keep immune system intact
  • Long term use is safe and well tolerated (3 times a week)

Read more Show less

Innopharmax Inc

  • Country/Region:
    Taiwan
  • Founded:
    2005
  • On CPHI since:
    2026
  • Employees:
    25 - 49
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    • Phase 2a BTC: Positive results observed in the Phase 2a study of INNO-GO-05, GemOral and Xeloda/TS-1 combo for 2L Biliary Tract Cancer (BTC) patients:  https://clinicaltrials.gov/show/NCT05065957
    • Phase 3 BTC: Phase 3 global pivotal study of D07001 GemOral for Biliary Tract Cancer (BTC) patients was initiated in 2025Q2 and ongoing. https://clinicaltrials.gov/study/NCT06622057
    • Huge potential in treating pancreatic cancer (Phase 1b observation: 4 out of 5 Pancreatic cancer R/R patients reach SD. All of them had been treated with standard of care for 2 years)
    • Phase 2/3 trial for late-stage Pancreatic cancer (PAC) and NSCLC is in development
    • Great Off-Label Use potential
    • Combination potential: Suitable for combination with oral target therapy seeking gemcitabine IV injection replacement.

More specifications Fewer specifications

Innopharmax Inc

  • Country/Region:
    Taiwan
  • Founded:
    2005
  • On CPHI since:
    2026
  • Employees:
    25 - 49
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile

More Products from Innopharmax Inc (7)

  • BendaReady, Bendamustine RTD injection

    Product BendaReady, Bendamustine RTD injection

    100 mg/4mL (25 mg/mL) as a ready to dilute solution in a multiple-dose vial

    Bendamustine HCl Injection RTD is an alkylating drug indicated for treatment of patients with: 
    • Chronic lymphocytic leukemia (CLL, Binet stages B & C) • Indolent B-cell non-Hodgkin lymphom...
  • MRI Contrast Agents (API & FDF)

    Product MRI Contrast Agents (API & FDF)

    Gadopentetate dimeglumine
    • FDF launch in China, 2025H1  (China FDF approval: H20244422, H20244423, H20244424) • US DMF 026647, Taiwan DMF 060348, China DMF YBY67662024 • Full dossier available Gadoterate meglumine
    • FDF approval in China, 2024/12 (approval # H20249640, H20249641, H202...
  • Sapropterin Dihydrochloride (API & FDF)

    Product Sapropterin Dihydrochloride (API & FDF)

    Sapropterin tablet is used as a supplement for those with a rare-genetic disorder called Phenylketonuria (PKU). People with PKU cannot metabolize phenylalanine due to either defective production of phenylalanine hydroxylase (PAH), or cannot produce a co-factor called BH4 to activate the enzyme. It is o...
  • Formulation development of BCS class II, III and IV drugs into oral form using OralPAS®, OralPAS Pro®, and MUCR drug delivery platforms

    Product Formulation development of BCS class II, III and IV drugs into oral form using OralPAS®, OralPAS Pro®, and MUCR drug delivery platforms

    • Self-MicroEmulsifying Drug Delivery System (SMEDDS) technology, can be applied with candidates of BCS class II, III, and IV small molecules that are difficult to absorb in oral form, or applied with peptide/protein (OralPAS Pro®) • The oral form enhances drug absorption through structural or fluidt...
  • INNO-029 Riociguat CR

    Product INNO-029 Riociguat CR

    Reduce the dosing frequency (TID to QD), once-daily controlled release based on proprietary MUCR system
  • INNO-027 Oral Teriparatide

    Product INNO-027 Oral Teriparatide

    505b2 new dosage form product based on OralPAS Pro platform - improved and cost-effective ORAL option compared to current SC treatments

  • N11005 Oral Insulin

    Product N11005 Oral Insulin

    •       First prandial oral insulin product made via OralPAS Pro® platform
    •       Rapid-acting (onset within 15 min) and short duration (2 hr), designed to mimic the physiological response to insulin in the control of postprandial hy...